NCT01202526

Brief Summary

Gastric bypass surgery induces remission of diabetes within days after surgery, before significant weight loss. The aim of the study is to examine whether improved insulin sensitivity of muscle and liver contributes to the immediate diabetes resolution.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2010

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2010

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

September 15, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 16, 2010

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2013

Completed
Last Updated

October 25, 2013

Status Verified

October 1, 2013

Enrollment Period

2.5 years

First QC Date

September 15, 2010

Last Update Submit

October 24, 2013

Conditions

Keywords

Insulin resistanceGastric bypass

Outcome Measures

Primary Outcomes (1)

  • Change in insulin sensitivity after RYGB

    1 week, 3 months, 1 year

Secondary Outcomes (1)

  • Change in insulin secretion in response to oral glucose after RYGB

    3 months, 1 year

Other Outcomes (1)

  • Change in insulin secretion after iv glucose-glucagon after RYGB

    1 week, 3months, 1 year

Study Arms (2)

RYGB patients with type 2 diabetes

Morbid obese patients with type 2 diabetes undergoing gastric bypass surgery

RYGB patients without type 2 diabetes

Morbid obese patients with normal glucose tolerance undergoing gastric bypass surgery

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Subjects are recruited from the outpatient clinic of endocrinology and gastrosurgical clinic at Hvidovre University Hospital

You may qualify if:

  • patients eligible for gastric bypass surgery
  • Verified type 2 diabetes or normal glucose tolerance by oral glucose tolerance test (OGTT)

You may not qualify if:

  • Treatment for Hyperthyroidism

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hvidovre University Hospital

Copenhagen, Hvidovre, DK-2650, Denmark

Location

Related Publications (2)

  • Wewer Albrechtsen NJ, Hartmann B, Veedfald S, Windelov JA, Plamboeck A, Bojsen-Moller KN, Idorn T, Feldt-Rasmussen B, Knop FK, Vilsboll T, Madsbad S, Deacon CF, Holst JJ. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia. 2014 Sep;57(9):1919-26. doi: 10.1007/s00125-014-3283-z. Epub 2014 Jun 3.

  • Bojsen-Moller KN, Dirksen C, Jorgensen NB, Jacobsen SH, Serup AK, Albers PH, Hansen DL, Worm D, Naver L, Kristiansen VB, Wojtaszewski JF, Kiens B, Holst JJ, Richter EA, Madsbad S. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes. 2014 May;63(5):1725-37. doi: 10.2337/db13-1307. Epub 2013 Nov 15.

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum, plasma, urine, muscle, subcutaneous fat, visceral fat

MeSH Terms

Conditions

Diabetes Mellitus, Type 2ObesityInsulin Resistance

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinism

Study Officials

  • Anna Kirstine Bojsen-Møller, MD

    Hvidovre University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

September 15, 2010

First Posted

September 16, 2010

Study Start

September 1, 2010

Primary Completion

March 1, 2013

Study Completion

March 1, 2013

Last Updated

October 25, 2013

Record last verified: 2013-10

Locations